ABSTRACT
INTRODUCTION In 2002, the Food and Drug Administration announced its current Good Manufacturing Practices (cGMPs) for the 21st century initiative (1). A critical objective of the initiative was to promote industry modernization. In accord with this objective, the Food and Drug Administration (FDA) has been encouraging pharmaceutical firms to adopt truly modern, robust aseptic processing technologies that will afford tangible safety benefits to sterile products.
